Randomized Controlled Trial of OnabotulinumtoxinA for Depression in Parkinson Disease
Phase of Trial: Phase I
Latest Information Update: 07 Aug 2019
Price : $35 *
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Depression
- Focus Therapeutic Use
- 02 Aug 2019 Status changed from recruiting to discontinued as it was unable to recruit required participants
- 28 Feb 2018 Planned End Date changed from 28 Feb 2018 to 15 Jul 2019.
- 28 Feb 2018 Planned primary completion date changed from 31 Dec 2017 to 30 May 2019.